Startup Wholomics has introduced a metabolomic platform employing nuclear magnetic resonance technology to detect cancer signatures across a broad spectrum of tumor types in serum samples. Unlike DNA-based methods, Wholomics focuses on metabolic, lipidomic, and lipoproteomic profiles that reflect functional tumor and microenvironment changes. Early and blinded clinical data presented at the American Society for Clinical Oncology demonstrate promising sensitivity for cancers such as pancreatic and colorectal tumors, offering a potentially powerful tool for early-stage detection and improved patient outcomes.